Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Potomac Pharma, Inc.
Not specified*, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Potomac Pharma, Inc. was a Maryland-based private biotech/pharmaceutical company focused on developing small molecule therapeutics targeting the alpha-2 adrenergic receptor for central nervous system disorders such as schizophrenia and cognition disorders. Its two main programs—P‑101 and Idazoxan Hydrochloride—were both discontinued before reaching late-stage clinical trials.[1][7] There are no recent reports of ongoing clinical results or new pipeline assets.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (e.g., ADRA2 antagonists such as Idazoxan Hydrochloride and P-101)
- Industry
- Biotech
Beyond the preview
Go deeper on Potomac Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potomac Pharma, Inc..